序号	中文	英文	操作
191	John Shriver, Sanofi, USA	John Shriver, Sanofi, USA	查看中文全文00003 查看英文全文00003
192	Gale Smith, Novavax Inc. USA	Gale Smith, Novavax Inc. USA	查看中文全文00003 查看英文全文00003
193	Peter Smith, London School of Hygiene and Tropical Medicine, UK	Peter Smith, London School of Hygiene and Tropical Medicine, UK	查看中文全文00003 查看英文全文00003
194	Isabel Sola, Centro Nacional Biotecnología, Spain	Isabel Sola, Centro Nacional Biotecnología, Spain	查看中文全文00003 查看英文全文00003
195	James Southern, Adviser to South African Health Products Regulatory Authority	James Southern, Adviser to South African Health Products Regulatory Authority	查看中文全文00003 查看英文全文00003
196	Jonathan M Spergel, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, USA	Jonathan M Spergel, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, USA	查看中文全文00003 查看英文全文00003
197	Sybil Tasker, Codagenix Inc, USA	Sybil Tasker, Codagenix Inc, USA	查看中文全文00003 查看英文全文00003
198	Chien-Te Kent Tseng, University of Texas Medical Branch, Galveston, Texas, USA	Chien-Te Kent Tseng, University of Texas Medical Branch, Galveston, Texas, USA	查看中文全文00003 查看英文全文00003
199	U.S. Department of Health and Human Services, USA, Assistant Secretary for Preparedness and Response/Biodefense Advanced Research and Development Authority	U.S. Department of Health and Human Services, USA, Assistant Secretary for Preparedness and Response/Biodefense Advanced Research and Development Authority	查看中文全文00003 查看英文全文00003
200	U.S. Department of Health and Human Services, USA, Centers for Disease Control and Prevention	U.S. Department of Health and Human Services, USA, Centers for Disease Control and Prevention	查看中文全文00003 查看英文全文00003